The Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing.

Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs.

The timing of cyclophosphamide therapy in tumor-bearing rats affects the resistance to tumor challenge in survivors.

Cyclophosphamide given to rats 2 or 5 days after an injection of Yoshida ascites sarcoma cured approximately the same proportion of animals, but the resistance to a subsequent tumor challenge was found only in rats treated with the drug 5 days after tumor injection.

Influence of the thymus on the incidence of secondary and parabiotic disease.

The secondary disease in P leads to F1 strain combination depends upon the immune status of both partners. It is most clearly expressed if both donors and recipients are immunologically crippled by thymectomy and irradiation. Conspicuous reduction in the immune potential of parental parabionts induced by thymectomy and irradiation displayed their marked incidence of parabiotic death.

Ascitic versus solid growth of Ehrlich ascites tumor influenced by immunological factors.

A certain number of CBA mice injected intraperitoneally with 1 X 10(6) or fewer Ehrlich ascites tumor (EAT) cells did not develop ascites tumors but solid tumors at the inoculation site. The incidence of solid tumors proved dependent on the level of immunological reactivity of recipients, being increased in mice with increased immunological potency and absent in mice in which this potency was reduced. Mice bearing solid tumors had increased level of cytotoxic antitumor antibodies in serum. Possible reasons for a greater immune resistance of cells growing in subcutaneous tissue, than in the abdominal cavity, are discussed.

Experimental allergic encephalomyelitis in T-lymphocyte deficient rats.

Thymectomized, lethally irradiated rats reconstituted with syngeneic bone marrow were injected with rat brain in complete Freund adjuvant mixture. Both, they and sham-thymectomized, irradiated and bone marrow protected rats displayed a higher incidence of leg paralysis than normal non-irradiated animals. Thymectomy lowered the incidence of the disease.

Yoshida ascites sarcoma grown in mice.

Xenogeneic Yoshida ascites sarcoma grows well in the abdominal cavity of thymectomized, irradiated mice reconstituted with syngeneic bone marrow. These animals displayed a 100-percent mortality. In control sham-thymectomized, irradiated mice reconstituted with syngeneic bone marrow mortality was significantly lower. The tumor growth could be neutralized by means of single intravenous injection of nonimmune spleen cells inoculated at the same time as the tumor. Tumor cells grown in mice killed normal rats and were rejected by normal mice.